Mirum reports success in late-stage hepatitis trial
Mirum Pharmaceuticals announced its experimental drug brelovitug successfully reduced virus levels in a late-stage study of hepatitis delta patients. The company plans to seek FDA approval in the first half of 2027.
Xurve View
Insights:
Xurve View
MIRUM PHARMACEUTICALS INC reported that its experimental hepatitis drug cut virus levels in a late-stage study on Monday morning. The treatment achieved its primary goal in patients with chronic hepatitis delta virus. The company projects peak sales of at least $1 billion for the therapy.
The monoclonal antibody, known as brelovitug, targets hepatitis B surface antigens. The infection impacts roughly 230,000 individuals across the United States and Europe, frequently resulting in severe liver damage.
